Guidelines on neuraminidase inhibitors in children are not supported by evidence [3]

British Medical Journal

Volumn 328, Issue 7433, 2004, Pages 227-

  Symmonds, Mkael ^a   Matheson, Nicholas J ^b   Harnden, Anthony ^c  

^a AYR HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE; SIALIDASE INHIBITOR;

ASTHMA; CHILD; CHILDHOOD DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; DISEASE DURATION; DRUG MARKETING; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INFLUENZA; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARD; STATISTICAL SIGNIFICANCE;

CHILD; EVIDENCE-BASED MEDICINE; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; PRACTICE GUIDELINES;

EID: 0742322087     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. National Institute for Clinical Excellence. Technology appraisal guidance No 58. London: NICE, 2003. http:// www.nice.org.uk/pdf/ 58_Flu_fullguidance.pdf
2. Matheson NJ, Symmonds-Abrahams M, Sheikh A, Shepperd S, Harnden A. Neuraminidase inhibitors for preventing and treating influenza in children (Cochrane Review). In: The Cochrane Library, Issue 3, 2003-Oxford: Update Software
3. European Agency for the Evaluation of Medicinal Products. Tamiflu. European Public Assessment Report 2002. http://www.eudra.org/humandocs/humans/ epar/ tamiflu/tamiflu.htm
4. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment 2002. http:// www.nice.org.uk/docref.asp?d=35650
5. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner DA, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235-40.